Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 10 mg /5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 20 mg /10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 40 mg/20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 5 mg/2,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - nicotinum - munnholsúði, lausn - 1 mg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - pentobarbitalum natríum - stungulyf, lausn - 400 mg/ml

Evrópusambandið - íslenska - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Æxlishemjandi lyf - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pharmaq as - tricaine methane sulfonate - baðduft til meðhöndlunar fiska, lausn - 1000 mg/g